AMYT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Apr 2024 @ 16:00):

Stats
Today's Volume	2.38M
Average Volume	0.00
Market Cap	942.77M
EPS	$0 ( 2023-05-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	39.73
ATR14	$0.0580 (0.39%)

Volume Correlation

Long: 0.18 (neutral)

Short: 0.00 (neutral)

Signal:(69.184) Neutral

Amryt Pharma plc Correlation

10 Most Positive Correlations
SUMO	0.97
DSPG	0.964
IDCC	0.946
NTUS	0.945
FSTR	0.945
STAY	0.941
HCCI	0.938
SENEA	0.935
SOHOB	0.935
ACLS	0.934

10 Most Negative Correlations
DSGN	-0.991
CSSE	-0.989
YTEN	-0.98
FWRD	-0.978
CASA	-0.974
THTX	-0.974
ESPR	-0.97
PFSW	-0.97
GRTX	-0.968
BBLG	-0.963

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amryt Pharma plc Correlation - Currency/Commodity

0.60
( weak )

0.57
( weak )

0.12
( neutral )

0.09
( neutral )

-0.56
( weak negative )

-0.51
( weak negative )

Amryt Pharma plc Financials

Annual	2021
Revenue:	$222.54M
Gross Profit:	$116.42M (52.32 %)
EPS:	$-0.573

Q3	2022
Revenue:	$61.13M
Gross Profit:	$27.42M (44.86 %)
EPS:	$-0.320

Q2	2022
Revenue:	$68.54M
Gross Profit:	$35.17M (51.32 %)
EPS:	$-0.110

Q1	2022
Revenue:	$59.13M
Gross Profit:	$28.35M (47.95 %)
EPS:	$-0.230

Financial Reports:

No articles found.

Amryt Pharma plc

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.